Says preliminary unaudited 2023 fiscal year revenue is expected to be approximately $89.1M, representing growth of approximately 82% compared to the prior year. Preliminary unaudited cash, cash equivalents and short-term investments as of December 31, 2023, is expected to be $127.2M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RXST:
- RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance
- RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
- RxSight price target raised by $7 at BTIG, here’s why
- RxSight price target raised to $43 from $36 at BTIG
- Microsoft initiated, Hertz downgraded: Wall Street’s top analyst calls
